Results 81 to 90 of about 162,445 (96)

Clinical update related to the first-in-human trial of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate.

Journal of Clinical Oncology
3151 Background: SYS6002 (CRB-701) is a novel, nectin-4 targeting antibody drug conjugate (ADC) that take advantage of a third generation, site-specific cleavable linker with novel conjugation chemistry.
Dingwei Ye, Jian Zhang, Hua Yang, Jin Yang, Tongsen Zheng, Hongmei Sun, Yuping Sun, Guiling Li, Funan Liu, Xuechao Wan, Lan Ge, G. Sun, Xiao Zhang, Lei Wang, Rachael Brake   +14 more
semanticscholar   +1 more source

Phase 1 dose escalation of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate (ADC).

Journal of Clinical Oncology
622 Background: Linker-conjugation of an ADC is a key feature in optimizing highly active and well tolerated agents. For maximal intra-tumoral delivery, linkers need to be highly stable in the systemic circulation yet allow for efficient drug release at ...
Dingwei Ye, Jian Zhang, Hua Yang, Jin Yang, Tongsen Zheng, Hongmei Sun, Xuechao Wan, Ge Lan, G. Sun, Xiao Zhang   +9 more
semanticscholar   +1 more source

Committee Opinion No 701: Choosing the Route of Hysterectomy for Benign Disease.

Obstetrics and Gynecology, 2017
Hysterectomy is one of the most frequently performed surgical procedures in the United States. Selection of the route of hysterectomy for benign causes can be influenced by the size and shape of the vagina and uterus; accessibility to the uterus; extent ...

semanticscholar   +1 more source

Fierce-21: Phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC).

Journal of Clinical Oncology, 2019
409 Background: Patients (pts) with mUC who have failed platinum-based chemotherapy have a poor prognosis. About 20% of them usually respond to immune checkpoint inhibitors (ICI).
A. Necchi, D. Castellano, B. Mellado, S. Pang, Y. Urun, S. Park, U. Vaishampayan, G. Currie, Esteban Abella-Dominicis, S. Pal   +9 more
semanticscholar   +1 more source

Is Your Career Hurting You? The Ergonomic Consequences of Surgery in 701 Urologists Worldwide.

Journal of endourology, 2019
Purpose Our objective was to seek correlations between the type, volume and duration of surgical work performed, surgeon habits and characteristics, and the prevalence of neck and back musculoskeletal complaint and intervention across career from ...
G. Lloyd, A. Chung, S. Steinberg, M. Sawyer, D. Williams, D. Overbey   +5 more
semanticscholar   +1 more source

Anti-BCMA BiTE® AMG 701 Potently Induces Specific T Cell Lysis of Human Multiple Myeloma (MM) Cells and Immunomodulation in the Bone Marrow Microenvironment

Blood, 2018
The first Bispecific T-cell Engager (BiTE®) targeting B-cell maturation antigen (BCMA) on multiple myeloma (MM) cells and CD3 on T cells is currently in clinical development (NCT02514239).
Shih-Feng Cho, Liang Lin, Lijie Xing, Jiye Liu, Tengteng Yu, Kenneth Wen, Phillip A. Hsieh, N. Munshi, K. Anderson, Y. Tai   +9 more
semanticscholar   +1 more source

Histone Deacetylase 701 (HDT701) Induces Flowering in Rice by Modulating Expression of OsIDS1

Molecules and Cells, 2018
Rice is a facultative short-day (SD) plant in which flowering is induced under SD conditions or by other environmental factors and internal genetic programs. Overexpression of Histone Deacetylase 701 (HDT701) accelerates flowering in hybrid rice. In this
Lae-Hyeon Cho, Jinmi Yoon, A. H. Wai, G. An   +3 more
semanticscholar   +1 more source

Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival.

, 2018
2058Background: SL-701 is a novel immunotherapy comprised of synthetic peptides designed to elicit an anti-tumor immune response against GBM targets: interleukin-13 receptor alpha-2, EphrinA2 and S...
D. Peereboom, L. Nabors, P. Kumthekar, M. Badruddoja, K. Fink, F. Lieberman, S. Phuphanich, E. Dunbar, T. Walbert, D. Schiff, D. Tran, L. Ashby, N. Butowski, F. Iwamoto, R. Lindsay, J. Bullington, M. Schulder, J. Sherman, T. Goswami, D. Reardon   +19 more
semanticscholar   +1 more source

FIERCE-21: Phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC).

, 2018
4534Background: Patients with locally advanced or metastatic urothelial carcinoma (mUCC) have a poor prognosis.
J. Bellmunt, J. Picus, M. Kohli, Y. Arriaga, M. Milowsky, G. Currie, S. Abella, S. Pal   +7 more
semanticscholar   +1 more source

Abstract 744: ADCT-701, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting DLK1-expressing tumors

Experimental and Molecular Therapeutics, 2018
Delta-like 1 homolog protein (DLK-1) is an EGF-like membrane bound protein consisting of six tandem EGF-like repeats, a juxtamembrane region with a TACE (ADAM17)-mediated cleavage site, a transmembrane domain, and a short intracellular tail.
F. Zammarchi, K. Havenith, S. Chivers, Paul W. Hogg, Charles E. Britten, Sandamali Dissanayake, P. Tyrer, F. Bertelli, I. Hutchinson, Luke A Masterson, P. Howard, J. Hartley, P. V. Berkel   +12 more
semanticscholar   +1 more source